Published 24 August 2011 IDC-GP Pharm has got license to market and distribute CEL-SCI's experimental cancer drug Multikine (Leukocyte Interleukin, Injection) in Argentina and Venezuela. Multikine is currently being developed as a treatment for head and neck cancer. Currently, CEL-SCI has existing licensing deals for Multikine with Teva Pharmaceuticals, Orient Europharma and Byron Pharmaceuticals. Pursuant to the agreement, IDC-GP Pharm will be responsible for receiving regulatory approval to use Multikine in the territory. Following the approval for the drug in any of the two countries, CEL-SCI will be responsible for manufacturing the product, while IDC-GP Pharm will be responsible for sales in the territory. CEL-SCI CEO Geert Kersten said this agreement is consistent with CEL-SCI's strategy to license Multikine in the emerging markets.
No comments:
Post a Comment